Core Viewpoint - Mihkel Torim will be elected as a new Member of the Supervisory Board and will assume the position of Chairman of the Management Board of AS LHV Group starting from 22 July 2025, following the resignation of Madis Toomsalu [1][4] Group 1: Leadership Changes - Mihkel Torim joined LHV at the beginning of 2023, managing and developing the investment banking operations of LHV Pank, and previously held senior positions at Swedbank [2] - Madis Toomsalu will resign as Chairman of the Management Board of LHV Group effective 22 July 2025, which will also terminate his mandates in other subsidiaries [4] Group 2: Shareholding and Options - Mihkel Torim does not currently hold shares in LHV Group but has the opportunity to acquire 199,575 shares through options granted to him in 2024 and 2025 [3] Group 3: Company Overview - LHV Group is the largest domestic financial group and capital provider in Estonia, with key subsidiaries including LHV Pank, LHV Varahaldus, LHV Kindlustus, and LHV Bank Limited, employing over 1,150 people [5] - As of the end of May, LHV's banking services are used by 471,000 clients, with 111,000 active clients in pension funds and 176,000 clients protected by LHV Kindlustus [5] - LHV Bank also offers retail banking services to private clients in the UK, loans to SMEs, and banking services to international fintech companies [5]

Core Viewpoint - Dupixent (dupilumab) has been approved by the US FDA as the only targeted treatment for adult patients with bullous pemphigoid (BP), a chronic skin disease primarily affecting the elderly [1][4][5]. Group 1: Disease Overview - Bullous pemphigoid primarily affects elderly patients and is characterized by intense itching, painful blisters, and skin lesions, leading to increased infection risk and impaired daily functioning [2][3]. - Current treatment options for BP are limited and often involve immunosuppressive therapies that can exacerbate the disease burden [2][3]. Group 2: Dupixent Approval and Efficacy - The FDA approval of Dupixent is based on the pivotal ADEPT phase 2/3 study, which demonstrated significant improvements in sustained disease remission and itch reduction compared to placebo [4][6][8]. - In the study, 18.3% of patients on Dupixent achieved sustained disease remission at 36 weeks compared to 6.1% for placebo, with a 12.2% difference [6][9]. - Additionally, 38.3% of patients on Dupixent experienced clinically meaningful itch reduction compared to 10.5% for placebo [6]. Group 3: Treatment Protocol and Safety - Dupixent is administered as a subcutaneous injection at a dosage of 300 mg every two weeks after an initial loading dose, in conjunction with a tapering course of oral corticosteroids [10][11]. - The most common adverse events (≥2%) observed in patients treated with Dupixent included arthralgia, conjunctivitis, and herpes viral infections [4][6]. Group 4: Broader Implications and Future Directions - Dupixent is now approved for treating eight distinct diseases associated with type 2 inflammation, indicating its potential to transform treatment paradigms for various conditions [5][7]. - The approval reinforces Dupixent's safety profile across a broad age range, with ongoing regulatory applications in other regions, including the EU, Japan, and China [7][13].

Core Points - CARBIOS, a pioneer in biological technologies for plastics and textiles, announced the results of its General Meeting held on June 19, 2025 [1] - The meeting saw 31.18% of shares represented, with all resolutions approved except for Resolution 21 [2] - The Board of Directors will now consist of 7 directors, including 3 independent directors, following the resignations of several members [4][5] Company Developments - The renewal of the term of office for several directors, including representatives from L'Oréal Development and Michelin Ventures, was approved [3] - Ms. Julie Sonies is proposed to be co-opted as an independent director to replace Ms. Sandrine Conseiller at the next Board meeting [6] - CARBIOS is recognized for its innovative biorecycling technologies and has operational plans for the world's first industrial biorecycling plant, expected to restart construction in the second half of 2025 [8]

Core Points - IDEX Biometrics ASA has completed a share issue to personnel, with the subscription and allocation finalized on June 19, 2025 [1] - Anders Storbråten and associated company Pinchcliffe AS will hold 975,635,000 shares in IDEX, representing 20.62% of the shares and voting rights following the capital increase [2] - The notice regarding the share issue was issued by CFO Kristian Flaten and complies with the Norwegian Securities Trading Act [2]

Group 1 - IDEX Biometrics ASA has completed a share issue to personnel, with subscription and allocation finalized on June 19, 2025 [1] - Sundt AS holds 230,491,498 shares in IDEX, representing 4.87% of the shares and voting rights following the capital increase [2] - The notice regarding the shareholding was issued by Kristian Flaten, CFO, on June 20, 2025, in compliance with the Norwegian Securities Trading Act [2]

Core Perspective - The Beijing International Film Festival made its Australian debut at the Sydney International Film Festival, promoting cultural exchange between Chinese cinema and Australian audiences [1][4]. Group 1: Event Highlights - The promotional event featured notable attendees including Bian Jian, Liu Dong, and David White, fostering a warm atmosphere for cultural exchange [3][4]. - Liu Dong emphasized the festival's role in promoting international film cooperation, particularly between China and Australia [4]. - The 15th Beijing International Film Festival received 1,794 film submissions from 103 countries, with foreign films making up nearly 90% of the total [6]. Group 2: Film Initiatives - The Tiantan Award Panorama, part of the "Never-ending Beijing Film Festival" campaign, aims to showcase high-quality Chinese films globally, with six films presented in Sydney [8]. - The festival's online presence generated over 3.5 billion views on Weibo and over 3.2 billion views on Douyin, indicating a strong cultural phenomenon [6]. Group 3: Industry Insights - David White highlighted the potential for collaboration between Australia and China in the film industry, especially in the context of a challenging global market [9]. - The Beijing International Film Festival aims to continue promoting cultural exchange and cooperation, focusing on storytelling as a key element for success [10].

Core Points - IDEX Biometrics ASA completed a share issue to personnel on 19 June 2025 following a prior notice on 15 June 2025 [1] - The company reported primary insider transactions as detailed in attached notifications [1] - The notice was issued by CFO Kristian Flaten on 20 June 2025, indicating compliance with EU Market Abuse Regulation and Norwegian Securities Trading Act [1] Attachments - Notifications related to primary insider transactions include notices from Annika Olsson, Morten Opstad, K Konsult, Caprock, and Anders Storbraten dated 19 June 2025 [2]

Core Viewpoint - Prime Mining Corp. successfully held its Annual General and Special Meeting, where all proposed directors were elected and all matters presented were approved, indicating strong shareholder support for the company's direction and governance [1][2]. Meeting Results - A total of 103,882,459 common shares were represented at the Meeting, accounting for 68.13% of the issued and outstanding common shares [2]. Election of Directors - The resolution to set the number of directors to nine was approved with 99.36% votes in favor [3]. - Individual nominees received significant support, with votes for key nominees as follows: - Murray John: 96.05% [4] - Scott Hicks: 99.57% [4] - Paul Sweeney: 96.99% [4] - Andrew Bowering: 94.72% [4] - Edie Hofmeister: 77.24% [4] - Marc Prefontaine: 98.59% [4] - Chantal Gosselin: 98.70% [4] - Kerry Sparkes: 79.96% [4] - Sunny Lowe: 96.98% [4] Appointment of Auditors - Davidson & Company LLP was approved as the auditor with 97.14% votes in favor [5]. Revised Omnibus Incentive Plan - The revised omnibus incentive plan was adopted with 95.59% votes in favor [7]. - Unallocated entitlements under the revised plan were approved with 87.65% votes in favor [8]. Financial Position - The company reported a cash balance of approximately $32.9 million as of June 17, 2025 [6]. Project Development - Prime Mining is focused on the Los Reyes gold-silver project in Sinaloa, Mexico, targeting a Preliminary Economic Assessment (PEA) completion by Q3 2025, which is expected to reflect a high return, high margin, low capital, and long-life project [6][14]. - The company has invested over $64 million in direct exploration activities since acquiring Los Reyes in 2019, completing over 221,000 meters of drilling [14]. Exploration Plans - Planned exploration activities include extending high-grade mineralization areas, expanding known resources, and conducting geological mapping and geochemical sampling to identify new targets [12][9]. - The company aims to engage with local communities through educational and environmental programs [12].

Core Insights - Telix Pharmaceuticals Limited is showcasing its innovative pipeline and commercial products at the SNMMI 2025 Annual Meeting, emphasizing its commitment to advancing cancer care through precision theranostics [1][3]. Group 1: Presentation Highlights - The ProstACT Global Phase 3 study of TLX591 in advanced prostate cancer will be presented, along with preclinical data on TLX252 alpha therapy in CAIX-expressing tumors [2]. - Clinical study data on the impact of Illuccix® on decision-making will also be featured [2]. - Two sponsored symposia will focus on CAIX-PET imaging in renal cancer and Illuccix PSMA-PET imaging in prostate cancer, including a new PSMA biopsy trial [2]. Group 2: Presentation Details - Key presentations include a Phase 3 study of TLX591 in combination with standard care for PSMA-expressing prostate cancer, scheduled for June 23 [4]. - Another presentation will discuss the enhanced antitumor efficacy of DNA damage response inhibitors combined with TLX252, taking place on June 24 [4]. - A prospective comparison of Ga-PSMA-11 PET/CT and Tc-PSMA-GCK01/RHN001DX SPECT/CT will also be presented [4]. Group 3: Satellite Symposia - The first symposium will address CAIX-PET imaging in renal cancer, scheduled for June 23 [6]. - The second symposium will focus on innovations in prostate cancer care with precision radiopharmaceuticals, also on June 23 [6]. Group 4: Company Overview - Telix is a biopharmaceutical company dedicated to developing therapeutic and diagnostic radiopharmaceuticals, headquartered in Melbourne, Australia, with operations in multiple countries [7]. - The company aims to address significant unmet medical needs in oncology and rare diseases through its clinical and commercial stage products [7]. - Illuccix®, Telix's first-generation PSMA-PET imaging agent, has received approval in various countries, while TLX591, TLX252, and RHN001Dx are still awaiting marketing authorization [8].

Core Viewpoint - FinVolution Group announced a proposed offering of convertible senior notes totaling US$130 million, with an option for an additional US$20 million, aimed at institutional buyers under Rule 144A of the Securities Act [1][9] Group 1: Notes Offering Details - The convertible senior notes will mature on July 1, 2030, unless repurchased, redeemed, or converted prior to that date [3] - Holders can convert their notes into cash, American Depositary Shares (ADSs), or a combination of both at the company's discretion [4] - The company plans to use the net proceeds from the offering for international business expansions, replenishing working capital, and funding a concurrent repurchase of ADSs [2] Group 2: Repurchase and Market Impact - The concurrent repurchase will involve buying back ADSs from certain purchasers of the notes, facilitating initial hedging for those investors [6] - The repurchase activities may influence the market price of the ADSs and the trading price of the notes [7][8] - The repurchase price for the notes will be equal to 100% of the principal amount plus any accrued interest [5] Group 3: Company Overview - FinVolution Group is a leading fintech platform in China, Indonesia, and the Philippines, established in 2007, focusing on connecting young borrowers with financial institutions [11] - As of March 31, 2025, the company had 216.2 million cumulative registered users across its platforms [11]